GZD856 formic 是一种有效的具有口服活性的 PDGFRα/β 抑制剂(IC50 值分别为 68.6 和 136.6 nM),同时也是 Bcr-AblT315I 的抑制剂(对天然 Bcr-Abl 和 T315I 突变型的 IC50 值分别为 19.9 和 15.4 nM),具有抗肿瘤活性。
产品编号: MS-F68364 纯度: 95.36% CAS No.: 2804039-78-7 分子式: C30H29F3N6O3 分子量: 578.58
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

GZD856 formic 是一种有效的具有口服活性的 PDGFRα/β 抑制剂(IC50 值分别为 68.6 和 136.6 nM),同时也是 Bcr-AblT315I 的抑制剂(对天然 Bcr-Abl 和 T315I 突变型的 IC50 值分别为 19.9 和 15.4 nM),具有抗肿瘤活性。

生物实验数据

生物活性 GZD856 formic is a potent and orally active PDGFRα/β inhibitor (IC50 values of 68.6 and 136.6 nM, respectively) that also inhibits Bcr-AblT315I (IC50 values of 19.9 and 15.4 nM for native Bcr-Abl and the T315I mutant, respectively) and exhibits antitumor activity.
IC50 & Target Bcr-Abl:19.9 nM, PDGFRβ:136.6 nM, BCR-ABL (T315I):15.4 nM, PDGFRα:68.6 nM
体外研究
(In Vitro)

GZD856 (0.0032-10 μM, 72 h) exerts antiproliferative activity against a panel of lung cancer cells.
GZD856 (0.3-3 μM; 24-28 h) induces a dose-dependent G0/G1 phase arrest and apoptosis in H1703 but not A549 cells.
GZD856 (0.1-10 μM; 6 h) dose-dependently inhibits the PDGFRα/β phosphorylation and downstream signaling in H1703 and A549 cells.
GZD856 inhibits the proliferation of K562, K562R (Q252H) and murine Ba/F3 cells ectopically expressing Bcr-AblWT and Bcr-AblT315I, with IC50s of 2.2, 67.0, 0.64 and 10.8 nM, respectively.

Cell Viability Assay

Cell Line: H1703, A549, Calu-6, 95-D, L-78, HCC827, SPCA-1, H1650, H1299, H522, H332 and H820 NSCLC cells
Concentration: 0.0032-10 μM
Incubation Time: 72 hours
Result: Inhibited PDGFRα-overexpressing H1703 cells, with an IC50 of 0.25 μM.

Apoptosis Analysis

Cell Line: H1703 and A549 NSCLC cells
Concentration: 0.3, 1, 3 μM
Incubation Time: 24, 48 hours
Result: Led to 54.1% apoptosis in H1703 cells at the concentration of 3.0 µM, whereas only 15.5% apoptotic A549 cells were observed under similar conditions.
Decreased the CDK4, cyclin D2, CDK2 and Cyclin E protein levels and activated of PARP and Caspase-3 cleavage in H1703 cells.

Western Blot Analysis

Cell Line: H1703 and A549 NSCLC cells
Concentration: 0.1-10 μM
Incubation Time: 6 hours
Result: Inhibited the phosphorylation of PDGFRα and PDGFRβ in a dose-dependent manner.
Observed the activation of downstream AKT, ERK1/2 and STAT3, with no obvious effects on total protein levels.
体内研究
(In Vivo)

GZD856 (10-30 mg/kg, p.o. once daily for 16 d) displays good antitumor activity in both H1703 and A549 lung cancer models and is well tolerated. GZD856 inhibits brain and liver metastasis of lung cancer cells in an A549-Luc orthotopic model.
GZD856 (10 mg/kg; p.o. once daily for 8 d) potently inhibits tumor growth in mouse bearing xenograft K562 and Ba/F3 cells expressing Bcr-AblT315I.
GZD856 (5 mg/kg; a single i.v.) exhibits a long half-life (T1/2=19.97 h), optimal plasma exposure (Cmax=934.38 μg/L) and a AUC0-∞ (8165.8 μg/L h) in rats.
GZD856 (25 mg/kg; a single p.o.) exhibits a long half-life (T1/2=22.2 h), optimal plasma exposure (Cmax=899.5 μg/L) and a good oral bioavailability (BA=78%) in rats.

Animal Model: Male CB17-SCID mice implanted with H1703 and A549 cancer cells
Dosage: 10, 30 mg/kg
Administration: Oral gavage once daily for 16 days
Result: Displayed antitumor effects in H1703-xenograft mice, with tumor growth inhibition (TGI) values of 20.8% and 74.1% at dosages of 10 and 30 mg/kg, respectively.
Displayed antitumor effects in A549-xenograft mice, with a TGI value of 51.1% at 30 mg/kg.
Was well tolerated in all of the tested groups, with no mortality or significant loss of body weight.
Animal Model: Sprague-Dawley (SD) rats (180-220 g)
Dosage: 5 mg/kg for i.v.; 25 mg/kg for p.o. (Pharmacokinetic Analysis)
Administration: A single intravenous injection and oral administration
Result: I.v.: T1/2=19.97 h; Cmax=934.38 μg/L; AUC0-∞=8165.8 µg/L•h.
P.o.: T1/2=22.2 h; Cmax=899.5 μg/L; BA=78%.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 578.58
分子式 C30H29F3N6O3
CAS No. 2804039-78-7

储存&溶解度

储存方式

-20°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (172.84 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.7284 mL8.6418 mL17.2837 mL43.2092 mL
5 mM0.3457 mL1.7284 mL3.4567 mL8.6418 mL
10 mM0.1728 mL0.8642 mL1.7284 mL4.3209 mL
15 mM0.1152 mL0.5761 mL1.1522 mL2.8806 mL
20 mM0.0864 mL0.4321 mL0.8642 mL2.1605 mL
25 mM0.0691 mL0.3457 mL0.6913 mL1.7284 mL
30 mM0.0576 mL0.2881 mL0.5761 mL1.4403 mL
40 mM0.0432 mL0.2160 mL0.4321 mL1.0802 mL
50 mM0.0346 mL0.1728 mL0.3457 mL0.8642 mL
60 mM0.0288 mL0.1440 mL0.2881 mL0.7202 mL
80 mM0.0216 mL0.1080 mL0.2160 mL0.5401 mL
100 mM0.0173 mL0.0864 mL0.1728 mL0.4321 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础